BioNTech (NASDAQ:BNTX) Price Target Lowered to $124.00 at JPMorgan Chase & Co.

BioNTech (NASDAQ:BNTX) had its price target decreased by JPMorgan Chase & Co. from $125.00 to $124.00 in a report released on Monday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Several other equities analysts have also issued reports on the company. UBS Group raised their price target on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. TD Cowen lifted their target price on shares of BioNTech from $85.00 to $132.00 and gave the stock a “hold” rating in a research note on Monday, October 21st. Deutsche Bank Aktiengesellschaft upped their price target on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, September 19th. Bank of America boosted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Finally, HC Wainwright increased their target price on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $134.69.

BioNTech Trading Up 1.2 %

BNTX stock opened at $107.88 on Monday. The company has a market capitalization of $25.65 billion, a PE ratio of -51.37 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company’s 50 day moving average price is $111.40 and its two-hundred day moving average price is $96.39.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.34%. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter last year, the company earned $0.73 EPS. The firm’s revenue was up 38.9% compared to the same quarter last year. As a group, analysts predict that BioNTech will post -2.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BNTX. Mirae Asset Global Investments Co. Ltd. grew its stake in BioNTech by 85.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 68,428 shares of the company’s stock worth $6,312,000 after purchasing an additional 31,615 shares during the period. Janney Montgomery Scott LLC bought a new stake in shares of BioNTech during the 1st quarter valued at $314,000. Capstone Investment Advisors LLC bought a new position in shares of BioNTech in the 1st quarter worth about $263,000. Lester Murray Antman dba SimplyRich increased its stake in shares of BioNTech by 30.2% in the 1st quarter. Lester Murray Antman dba SimplyRich now owns 3,112 shares of the company’s stock worth $288,000 after acquiring an additional 721 shares in the last quarter. Finally, Coulter & Justus Financial Services LLC purchased a new position in shares of BioNTech during the first quarter valued at approximately $231,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.